Study Title
TAK-620-2004: A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Protocol ID
TAK-620-2004
Disease (Sub Disease)
Cytomegalovirus (CMV)
Diagnosis Stage
Previously treated
Location
NSW, QLD, WA
Sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Links
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 17 Years
International registry ID's
NCT05319353
| Study Title | TAK-620-2004: A Phase 3 Open-label Single-arm Repeated-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
|---|---|
| Protocol ID | TAK-620-2004 |
| Disease (Sub Disease) | Cytomegalovirus (CMV) |
| Diagnosis Stage | Previously treated |
| Location | NSW / QLD / WA |
| Sponsor | Takeda |
| Collaborators | Takeda Development Center Americas, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT05319353 |
| Trial Status | Open |
| Trial Open Date | 29/05/2024 |
| Sites | Perth Children's Hospital/ Sydney Children's Hospital/ Queensland Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 17 Years |
| International registry ID's | NCT05319353 |